Genson Capital

Their thesis, in full

Genson Capital is a Montreal-based private investor specializing in life sciences and MedTech, associated with the Courtois family and operating like a family office rather than a conventional fund with disclosed LPs. It invests directly in companies and is willing to lead, writing early cheques from pre-seed through Series A, with disclosed bets including Morphocell, Neurenati and Vopemed. Founders should understand there is no public website or open application process: this is a relationship-driven investor reached through warm introductions and Quebec life-sciences networks. It gravitates toward science-heavy healthtech and biotech, often emerging from Montreal research institutions such as CHU Sainte-Justine and Universite de Montreal. Realistically, the best path in is a credible referral from a co-investor (for example Investissement Quebec) or a portfolio founder, paired with strong clinical or technical proof. Treat Genson as a conviction-led, low-profile lead investor for Quebec life-sciences companies rather than a high-volume seed shop.

Questions they usually ask

Have an answer ready for each one before the first call.

1. What is your clinical or technical proof point to date (preclinical data, regulatory pathway, IP position), and what does the next 18 months of validation require?
2. Are you a Quebec-based life-sciences or MedTech company, ideally with ties to the local research ecosystem, and who in that network can vouch for you?
3. How much are you raising, who else is in or circling the round (for example Investissement Quebec), and would Genson be leading or following?

Follow-on

Genson backs a small number of science-driven healthtech and biotech companies and stays close, including taking board seats (President Jacques Courtois Jr. sits on Morphocell's board). It tends to anchor early rounds and then help bring in institutional co-investors and non-dilutive partners over time. Support is hands-on and relationship-based rather than program or platform-driven.